Induction of beta-2-microglobulin release in vitro by chronic lymphocytic leukaemia cells: relation to total protein synthesis

Vilpo, Juhani; Vilpo, Leena; Hurme, Mikko; Vuorinen, Pauli

doi:10.1016/s0145-2126(99)00109-5

Cited by 12 publications

(17 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3,4 Density gradient centrifugation yields, without other purification steps, were good (range 29-92%; mean 61.7%; s.d. 16.2%, n = 36).…”

Section: To the Editormentioning

confidence: 95%

“…as recently described. 3,4 We have previously shown that all tested mitogens and their combinations induce a powerful activation and proliferation response when assessed with freshly isolated cells in 4-day cultures (see above). We confirmed here that every mitogen and mitogen combination induced a significant increase in leukemia cell proliferation when tested by using the Wilcoxon matched pair test (P Ͻ 0.00001, n = 30).…”

Section: To the Editormentioning

confidence: 98%

“…Thirty analyses of fresh cells and 53 analyses of cryopreserved cells were performed in suspension cultures: (1) proliferation analysis after OMC stimulation in 4-day cultures, by using thymidine incorporation, and (2) activation analysis by using leucine incorporation or total protein synthesis as an end point. 3,4 In all cases, proliferation and activation The growth potential of CLL cells was also investigated at the single cell level. 10 5 cells were seeded in suspension in 200 l semisolid methylcellulose (50% Methocult GF H4534, Stemcell Technologies, Vancouver, BC, Canada) in 96-well microtiter plates.…”

Section: To the Editormentioning

confidence: 99%

See 2 more Smart Citations

Short-term growth potential of cryopreserved B chronic lymphocytic leukemia cells in suspension and in semisolid medium

Vilpo

2001

Leukemia

View full text Add to dashboard Cite

“…3,4 Density gradient centrifugation yields, without other purification steps, were good (range 29-92%; mean 61.7%; s.d. 16.2%, n = 36).…”

Section: To the Editormentioning

confidence: 95%

Section: To the Editormentioning

confidence: 98%

Section: To the Editormentioning

confidence: 99%

See 1 more Smart Citation

Short-term growth potential of cryopreserved B chronic lymphocytic leukemia cells in suspension and in semisolid medium

Vilpo

2001

Leukemia

View full text Add to dashboard Cite

“…17,19 Proliferation per se was not significantly associated with antigen expression changes (Table 4). Surprisingly, a negative correlation was observed concerning CD5 and CD11c, showing that suppressed proliferation was associated with strong upregulation of these antigens.…”

Section: Association Of Membrane Antigen Expression Changes With Prolmentioning

confidence: 96%

“…For this purpose, the most effective mitogen combination for each patient was chosen from a panel of 14 combinations of four B-CLL cell mitogens, as previously described. [17][18][19] …”

Section: Introductionmentioning

confidence: 99%

Surface membrane antigen expression changes induced in vitro by exogenous growth factors in chronic lymphocytic leukemia cells

et al. 2002

View full text Add to dashboard Cite

The factors determining the growth and survival of cells in B chronic lymphocytic leukemia (CLL) have remained poorly understood. We investigated the effects of optimal mitogen combinations (OMCs) on the expression of 26 surface membrane antigens among 33 CLL patients. The seven OMCs used were selected after pre-testing 14 combinations of (1) S. aureus Cowan I (SAC), (2) interleukin-2 (IL-2), (3) tumor necrosis factor alpha (TNF-␣) and (4) 12-O-tetradecanoylphorbol 13-acetate (TPA; also known as phorbol 12-myristate 13-acetate or PMA). In flow cytometry we revealed that OMCs induced statistically highly significant upregulation of the expression of CD5, CD11c, CD19, CD22, CD23, CD25, CD38, CD40, CD45, CD45RO, CD95, CD126, CD130 and FMC7, and downregulation of CD20 and CD124 expression. Interestingly, the expression of CD27, CD45RA, CD79b, CD80, CD122 and that of the immunoglobulin gene superfamily members CD21, Ig-, Ig-, Ig-␦ and Ig-were not significantly affected under similar conditions. The expression of several antigens was co-regulated, suggesting common regulatory pathways. These antigens include CD11c/CD5, CD11c/CD22, CD11c/CD126, CD11c/FMC7 as well as CD27/CD45, CD27/CD45RA and CD27/CD79b. Upregulation of surface antigen expression, induced by OMCs, should be applicable in antibody therapy in vitro and in vivo, and in negative stem cell selection for autotransplantation. Furthermore, the current strategy to enhance cell surface antigen expression may be a versatile tool to raise humoral and cell-mediated host defense against CLL cells. Upregulation of proteins mediating positive growth signals (eg CD25, CD40) and negative signals or apoptosis (eg CD95) may be used to sensitize cells to chemotherapy and programmed cell death.

show abstract

Prognostic value of plasma interleukin‐6 levels in patients with chronic lymphocytic leukemia

Lai

O’Brien

Maushouri

et al. 2002

Cancer

View full text Add to dashboard Cite

BACKGROUND. Interleukin 6 (IL-6) is a B-cell growth and differentiation factor, which may promote the growth of B-cell neoplasms. In chronic lymphocytic leukemia (CLL) patients, IL-6 plasma levels increased in a stage-dependent manner, suggesting that IL-6 may be a useful prognostic marker. The purpose of this study is to fully assess the prognostic value of IL-6 in CLL patients. METHODS. We measured the plasma levels of IL-6 in 100 CLL patients using an enzyme-linked immunoassay method. RESULTS. Increasing levels of IL-6 significantly correlated with patient age, severity of anemia, Rai stage, white cell count, and ␤-2-microglobulin (␤-2M). Although CLL patients did not differ significantly from the normal controls in the median IL-6 plasma level (P ϭ 0.38), patients with advanced diseases (defined by Rai stage III/IV or ␤-2M Ͼ 3.5) had a significantly higher median IL-6 plasma level than the normal controls (P Ͻ 0.05). Furthermore, in patients with advanced diseases, Cox regression hazards model showed that a higher IL-6 level correlated with shorter survival (P ϭ 0.0001). Using IL-6 level of 3 pg/mL as a cutoff, patients with low IL-6 levels had a significantly longer overall survival than those with high IL-6 levels (log rank test, P ϭ 0.002). In patients with CD38-positive CLL, patients with high IL-6 levels (Ͼ 3 pg/mL) had significantly shorter survival (P ϭ 0.03). To conclude, IL-6 is a particularly useful predictor for survival in CLL patients with advanced diseases. CONCLUSIONS. Our findings suggest that patients with advanced-stage CLL as well as high IL-6 plasma levels may require aggressive therapeutic approaches and special consideration for experimental therapy.

show abstract

Induction of beta-2-microglobulin release in vitro by chronic lymphocytic leukaemia cells: relation to total protein synthesis

Cited by 12 publications

References 20 publications

Short-term growth potential of cryopreserved B chronic lymphocytic leukemia cells in suspension and in semisolid medium

Short-term growth potential of cryopreserved B chronic lymphocytic leukemia cells in suspension and in semisolid medium

Surface membrane antigen expression changes induced in vitro by exogenous growth factors in chronic lymphocytic leukemia cells

Prognostic value of plasma interleukin‐6 levels in patients with chronic lymphocytic leukemia

Contact Info

Product

Resources

About